oral allergy syndrome (OAS)
Conditions
Interventions
Because there is no allergen extract of birch pollen approved for use in therapy at the moment in Japan, we use Birch Mix for injection made by ALK-Abello (USA). We have obtained certification from th
Sponsors
Kanagawa Children's Medical Center Department of Allergy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Persons who have been sensitized with birch pollen (specific IgE>0.7 UA/mL, ImmunoCAP) and suffer from OAS symptoms by ingestion of fruits or vegetables.
Exclusion criteria
Exclusion criteria: Severe immune abnormality or immunodeficiency, malignancy, severe mental disorder, use of beta blocker, poor compliance, uncontrolled asthma, use of cardiovascular drugs increasing a side effect of the adrenaline, pregnancy, etc..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the change in OAS symptoms after the treatment, which is evaluated by oral food challenge test with numerical rating scale (NRS) before and at some time points after the treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| We also measure nonspecific IgE, specific IgE and specific IgG4 to birch pollen and causative foods before and after the treatment. | — |
Countries
Japan
Contacts
Public ContactShuntaro Tsumagari
Kanagawa Children's Medical Center Department of Allergy
Outcome results
None listed